Taysha Gene Therapies Q3 net loss widens on higher R&D costs
Overview
US gene therapy developer's Q3 net loss widened yr/yr due to higher R&D and admin expenses
Company reported no revenue for Q3 2026
TSHA-102 trials showed no severe treatment-related adverse events as of November 2026 data cutoff
Outlook
Company expects topline data from REVEAL pivotal trial 6-month interim analysis in 1H 2027
FDA feedback on BLA submission pathway for TSHA-102 expected in 1H 2027
Company expects to nominate a new gene therapy candidate and begin preclinical work in 1H 2027
Result Drivers
HIGHER CLINICAL TRIAL COSTS - Co said increased R&D expenses were mainly due to higher clinical expenses from REVEAL, pivotal and ASPIRE trials for TSHA-102
INCREASED ADMINISTRATIVE COSTS - Co attributed higher G&A expenses to increased compensation and commercial launch-readiness initiatives
MANUFACTURING MILESTONE - Co completed BLA-enabling manufacturing campaign for TSHA-102, meeting product specifications and comparability criteria
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.10 | ||
Q3 Net Loss | $39.13 mln | ||
Q3 Operating Expenses | $41.87 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Taysha Gene Therapies, Inc. is $12.00, about 180.4% above its November 11 closing price of $4.28
Reuters Recommended Reads
Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs
Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs
Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)